AKT1 and non-small cell lung carcinoma: In non-small cell lung cancer, LINC00665 upregulates EZH2, an important component of the initiation complex (PRC2), thereby activating the PI3K/AKT signaling pathway and mediating EGFR expression, weakening the inhibition of EGFR kinase by the drug gefitinib [6].